Abbott's Receives FDA Approval For Esprit BTK Everolimus Eluting Resorbable Scaffold System
Abbott Laboratories -0.74%
Abbott Laboratories ABT | 116.12 | -0.74% |
- More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment options
- The first-of-its-kind Esprit™ BTK Everolimus Eluting Resorbable Scaffold dissolves over time after it has opened blocked arteries below the knee (BTK)
- The Esprit BTK System is a dissolving stent that offers the possibility of better outcomes for people with the most severe form of PAD
